Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance

Journal: Science Translational Medicine

Published: 2020-01-15

DOI: 10.1126/scitranslmed.aax9340

Affiliations: 18

Authors: 20

Go to article
Institutions Share
Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom (UK) 0.15
Department of Haematology, University of Cambridge, United Kingdom (UK) 0.15
Department of Internal Medicine III, Ulm University, Germany 0.10
UCL Great Ormond Street Institute of Child Health (ICH), United Kingdom (UK) 0.10
Cambridge Institute of Therapeutic Immunology and Infectious Diseases (CITIID), University of Cambridge, United Kingdom (UK) 0.10
TUM Institut für Klinische Chemie und Pathobiochemie, Germany 0.05
TUM Center for Translational Cancer Research (TranslaTUM), Germany 0.05
Faculty of Medicine, MUN, Canada 0.05
College of Nursing and Health Sciences (CNHS), UVM, United States of America (USA) 0.05
Cancer Cluster Salzburg (CCS), Austria 0.03
UiO Department of Immunology (IMM), Norway 0.03
UCSF Department of Laboratory Medicine, United States of America (USA) 0.03
The University of Vermont Cancer Center, UVM, United States of America (USA) 0.03
Department of Biochemistry, UVM, United States of America (USA) 0.03
German Consortium of Translational Cancer Research (DKTK), Germany 0.03
TUM School of Medicine, Germany 0.03
Salzburg Cancer Research Institute (SCRI), Austria 0.02

Return